Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ: GNPX) signed a Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN biomarkers that may predict response to REQORSA (quaratusugene ozeplasmid) gene therapy for NSCLC and SCLC. Research aims to refine patient selection for Acclaim-1 and Acclaim-3 trials and optimize outcomes.
Acclaim-1 (REQORSA + Tagrisso) completed Phase 1 dose escalation with no dose-limiting toxicities and showed early efficacy, including three of 12 patients with prolonged PFS and one patient with a partial response maintained through ~42 months. Acclaim-3 (REQORSA + Tecentriq) moved to Phase 2 after a Phase 1 with no DLTs and one unconfirmed partial remission.
Genprex (NASDAQ: GNPX) collaborators presented positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at AACR 2026 (April 17-22). Studies showed 79% tumor shrinkage with Quar Oze plus alectinib in an ALK+ sensitive model (p=0.0135) and synergistic tumor reduction and survival benefit in an alectinib-resistant model (p=0.0001).
Additional findings: TROP2 low/PTEN high associated with primary resistance; Quar Oze restored NK cell activity, producing complete tumor regression in preclinical cohorts (up to 67%). All data are preclinical.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at the AACR Annual Meeting, April 17-22, 2026.
Key findings: Quar Oze induced up to 79% tumor shrinkage in ALK+ models (p=0.0135), synergized with alectinib (p=0.0001), drove complete regressions in mice (67% Tusc2 KO, 33% WT), and identified TROP2 low/PTEN high as potential resistance biomarkers.
Genprex (NASDAQ: GNPX) announced that its executive leadership will attend BIO Europe Spring in Lisbon, Portugal, March 23-25, 2026. Attendees include Ryan Confer, President and CEO, and Thomas Gallagher, SVP of Intellectual Property and Licensing.
Genprex said executives will be available for one-on-one meetings to provide overviews of the company’s gene therapy programs for cancer and diabetes; meeting requests can be made via the conference portal or investors@genprex.com.
Genprex (NASDAQ:GNPX) announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent for REQORSA in combination with PD-L1 antibodies, and the European Patent Office issued a decision to grant a patent for REQORSA with PD-1 antibodies.
Genprex maintains exclusive licenses and says these patents strengthen protection for therapeutic combinations, including the Acclaim-3 small cell lung cancer trial combining REQORSA with PD-L1 antibodies. The company already holds related U.S. and Korea patents, and other international grants and pendings.
Genprex (NASDAQ: GNPX) announced IP Australia issued a Notice of Acceptance on Feb 5, 2026, for a patent application claiming use of Reqorsa® gene therapy combined with PD-L1 antibodies to treat cancers.
The company notes related patents are already granted in the U.S. and Korea and says the patent, if granted, will strengthen exclusivity in Australia while it advances the Acclaim-3 clinical trial and opens an additional site at the University of Kentucky.
Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.
Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.
Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.
Genprex (NASDAQ: GNPX) reported publication of Acclaim-1 Phase 1 data in Clinical Lung Cancer on Nov 24, 2025, evaluating REQORSA (quaratusugene ozeplasmid) with osimertinib in advanced EGFR-mutant NSCLC after progression on prior osimertinib.
The Phase 1 dose-escalation (12 patients) found no dose-limiting toxicities, set a recommended Phase 2 dose (RP2D) of 0.12 mg/kg, and reported early signs of efficacy including one investigator-assessed partial remission continuing >32 months and two patients with prolonged progression-free survival.
Genprex (NASDAQ: GNPX) announced on November 19, 2025 that it added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of Reqorsa gene therapy (quaratusugene ozeplasmid) in lung cancer.
The company noted the Acclaim trials are supported by FDA Fast Track designation and said it expects to add additional sites over the coming months to expand patient access and expedite enrollment.